Clinical Trial Update: TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [Phase 3]

View source ↗

Summary

Phase 3 study TRITON-CM is evaluating Nucresiran in patients with transthyretin amyloidosis with cardiomyopathy, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis with Cardiomyopathy

Drugs mentioned

• Nucresiran (Nucresiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Status: RECRUITING